Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
ONC201 is a new drug candidate that kills cancer cells but not normal cells in laboratory
studies and has been previously evaluated in a phase I clinical trial in advanced cancer
patients. This clinical trial will enroll patients with recurrent glioblastoma or recurrent
WHO Grade IV gliomas with the H3 K27M mutation.